Waterpipe Smoking And The DRD2/ANKK1 Genotype.
BACKGROUND
Waterpipe smoking is increasingly a worldwide phenomenon. Few studies have been conducted on the epidemiology of waterpipe smoking behavior and its genetic determinants. A polymorphism (TaqI) in the 3' untranslated region of the dopamine receptor gene (DRD2), later localized to the neighboring ANKK1 gene, has been previously linked to cigarette smoking. Since all tobacco products share the ability of stimulating the dopaminergic reward system, variation in the DRD2 genotype might be associated with waterpipe smoking addiction.


OBJECTIVE
This study aims to explore genetic variations in DRD2 gene and waterpipe smoking, motives and addiction in Egyptian rural males.


METHODS
The subjects (N=154) were selected from participants in a household smoking prevalence survey if they were adults, males, currently smoking waterpipe and not smoking cigarettes. Participants were interviewed about their smoking behaviors. Blood samples were genotyped by polymerase chain reaction (PCR). Subjects were subsequently classified as either the A1 (presence of at least one A1 allele) or A2 group (A2 homozygotes).


RESULTS
The prevalence of A1 genotype was 34.4 % in current waterpipe users, and was associated with the maximum duration before smokers experienced craving to smoke: after adjusting for age of smoking initiation, smoking for addictive motives, and average daily tobacco consumption, the A1 carriers were more likely to experience craving within a shorter duration after abstinence (the first 24 hours) compared to subjects with A2/A2 genotype (Odds ratio [OR] 2.70, 95% confidence interval [CI]: 1.18 - 6.23). In addition, the frequent visitors of shisha cafes were more likely to be younger, heavy smokers and carriers of A1 allele (OR, 2.52, 95% CI: 1.06-6.02).


CONCLUSIONS
This study revealed that the maximum duration before experiencing craving to smoke waterpipe and frequency of visiting cafés to smoke may be influenced by an inherited variations in the DRD2 genotype.
Dept. of Public Health, Cairo University, Cairo, Egypt. gnasr@theunion.org.
Ghada N
GN
Radwan
Christopher A
CA
Loffredo
Maged A
MA
El Setouhy
Mohamed
M
Abdel Hamid
Ebenezer J
EJ
Israel
Mostafa K
MK
Mohamed
Trends Pharmacol Sci. 2003 Sep;24(9):493-9
12967775
Nicotine Tob Res. 2005 Feb;7(1):149-56
15804687
Health Psychol. 1999 Jan;18(1):14-20
9925041
Nicotine Tob Res. 2004 Aug;6(4):583-97
15370155
Oncogene. 2002 Oct 21;21(48):7412-20
12379882
Health Psychol. 1999 Jan;18(1):7-13
9925040
Lancet. 2006 May 27;367(9524):1710-2
16731252
Mol Psychiatry. 2005 Apr;10(4):407-14
15381926
JAMA. 1990 Apr 18;263(15):2055-60
1969501
Tob Control. 2002 Jun;11(2):119-24
12035004
Food Chem Toxicol. 2003 Jan;41(1):143-52
12453738
Chest. 2003 May;123(5):1730-9
12740294
Pharmacol Biochem Behav. 2005 Jan;80(1):173-9
15652393
Zh Vyssh Nerv Deiat Im I P Pavlova. 2006 Jul-Aug;56(4):457-63
17025189
Nicotine Tob Res. 2007 Dec;9(12):1325-9
18058350
Hum Mutat. 2004 Jun;23(6):540-5
15146457
Brain Res Cogn Brain Res. 2005 Dec;25(3):851-61
16289773
Pharmacogenomics J. 2005;5(1):21-9
15492764
Int J Clin Pharmacol Ther. 2002 Jun;40(6):249-55
12078938
Br J Addict. 1991 Sep;86(9):1119-27
1932883
Pharmacol Biochem Behav. 2001 Dec;70(4):439-46
11796143
J Natl Cancer Inst. 1999 Aug 18;91(16):1365-75
10451441
Addict Behav. 2004 Sep;29(7):1275-94
15345265
Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1021-6
11045783
J Pers. 2000 Dec;68(6):999-1029
11130742
Proc Natl Acad Sci U S A. 1989 Dec;86(24):9762-6
2532362
Nicotine Tob Res. 2007 Oct;9(10):987-94
17943617
J Abnorm Psychol. 2002 Feb;111(1):134-43
11866166
Addict Behav. 2000 Sep-Oct;25(5):653-62
11023009
Am J Med Genet B Neuropsychiatr Genet. 2003 Apr 1;118B(1):48-54
12627466
Bull World Health Organ. 2000;78(11):1306-15
11143190
J Drug Educ. 2006;36(1):47-58
16981639
Addict Behav. 2006 Feb;31(2):232-45
15953689
Addict Biol. 2001 Apr;6(2):109-117
11341850
Saudi Med J. 2004 Jul;25(7):912-7
15235699